At #JPM23, another rare disease buyout as Ipsen acquires Albireo for $952M
Before most JPMers arose Monday morning, Ipsen announced that it is buying rare disease biotech Albireo Pharma. That’s the second deal disclosed Monday morning, along with AstraZeneca grabbing cardiovascular upstart CinCor Pharma. With the Chiesi-Amryt rare disease deal…#cholestatic #roncooper #medicines #albireo #arena #epizyme #vielabio #albo #expanded #into2024
Source: Reuters: Health - Category: Consumer Health News Source Type: news